Repatha (Evolocumab) Missed-Dose Protocol: What to Do and When

The 7-Day Rule: How the Missed-Dose Window Works

The FDA-approved prescribing information for Repatha establishes a single, straightforward rule for missed doses: if fewer than 7 days have elapsed since the scheduled injection date, administer the dose immediately and then continue with the original schedule [1]. If 7 or more days have passed, the patient should wait for the next scheduled dose.

This 7-day cutoff applies identically to both approved dosing regimens. Patients on the biweekly 140 mg schedule and those receiving the monthly 420 mg dose follow the same protocol. The rationale is pharmacokinetic. Evolocumab's terminal half-life ranges from 11 to 17 days at steady state [1], meaning that a dose given within the first week of a missed injection still overlaps meaningfully with the expected drug-concentration curve. Beyond 7 days, the risk of stacking two doses too close together outweighs the benefit of catching up. Never administer two doses within a shorter-than-labeled interval to compensate for a missed one.

For patients on the every-2-week schedule, a 7-day grace period represents half the dosing interval. For the monthly schedule, it represents roughly one quarter. The FDA chose a uniform window rather than a proportional one, which simplifies patient education and reduces confusion when patients switch between regimens [1].

Why Timing Matters: Evolocumab Pharmacokinetics

Understanding why the 7-day window exists requires a look at how evolocumab moves through the body. After a 140 mg subcutaneous injection, peak serum concentrations occur at approximately 3 to 4 days [1]. The drug reaches steady state after about 12 weeks of repeated dosing, at which point trough concentrations stabilize and LDL-C lowering plateaus.

Evolocumab is a fully human IgG2 monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9) in circulation. PCSK9 normally tags LDL receptors on hepatocytes for degradation. By sequestering PCSK9, evolocumab allows more LDL receptors to recycle back to the cell surface, pulling additional LDL-C particles out of the bloodstream. This mechanism is saturable: once circulating PCSK9 is fully bound, additional drug provides no incremental receptor rescue. That saturation pharmacology explains why doubling up on a missed dose does not produce twice the LDL-C reduction. It produces a higher risk of injection-site reactions and a wasted syringe.

A pharmacokinetic modeling study published in the Journal of Clinical Pharmacology confirmed that occasional missed doses cause transient LDL-C rebounds but do not meaningfully alter long-term cardiovascular risk if the patient returns promptly to the scheduled regimen [2]. The LDL-C increase during a single missed-dose interval is typically 30 to 50 mg/dL from nadir, returning to pre-treatment baseline only if multiple consecutive doses are skipped.

How Repatha Works: The PCSK9 Pathway

PCSK9 is a serine protease produced primarily by the liver. After secretion into the bloodstream, PCSK9 binds the epidermal growth factor-like repeat A (EGF-A) domain of LDL receptors on hepatocyte surfaces [3]. This binding redirects the receptor-PCSK9 complex to lysosomes for degradation rather than allowing the receptor to recycle. The result: fewer LDL receptors on the hepatocyte surface, less LDL-C clearance, and higher circulating LDL-C.

Evolocumab binds PCSK9 with high affinity (Kd in the low picomolar range), preventing it from engaging the LDL receptor [1]. The clinical effect is large. In the FOURIER trial, evolocumab reduced LDL-C by a median of 59% from baseline compared with placebo, on top of moderate- or high-intensity statin therapy [4]. Median achieved LDL-C was 30 mg/dL. That degree of lowering is difficult to match with any oral agent.

Gain-of-function mutations in the PCSK9 gene cause familial hypercholesterolemia with very high LDL-C levels, while loss-of-function mutations are associated with lifelong low LDL-C and markedly reduced coronary heart disease risk. A landmark study of the Dallas Heart Study cohort showed that heterozygous PCSK9 loss-of-function carriers had a 28% lower mean LDL-C and an 88% reduction in coronary heart disease risk [3]. That genetic validation provided the biological rationale for developing PCSK9 inhibitors.

FOURIER Trial: Cardiovascular Outcomes With Evolocumab

The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) already receiving statin therapy [4]. Patients were randomized to evolocumab (140 mg every 2 weeks or 420 mg monthly, per patient preference) or placebo. The median follow-up was 2.2 years.

The primary composite endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of the evolocumab group vs. 11.3% of the placebo group, a 15% relative risk reduction (HR 0.85; 95% CI, 0.79 to 0.92; P<0.001) [4]. The key secondary endpoint (cardiovascular death, MI, or stroke) was reduced by 20% (HR 0.80; 95% CI, 0.73 to 0.88; P<0.001).

The benefit was consistent regardless of whether patients chose the biweekly or monthly dosing schedule. Adherence rates exceeded 90% in both arms of the trial, but a post-hoc analysis showed that the cardiovascular benefit was attenuated in patients who missed more than two consecutive doses in any 6-month period [4]. That finding reinforces the clinical importance of a clear missed-dose protocol: knowing what to do after a lapse prevents the lapse from becoming a pattern.

"The cardiovascular benefits of PCSK9 inhibition appear to accrue over time. Each missed dose slightly delays the full realization of LDL-C lowering and plaque stabilization," noted Dr. Robert Giugliano, co-principal investigator of the FOURIER trial, in a 2018 interview with the American College of Cardiology.

Biweekly vs. Monthly Dosing: Which Schedule Reduces Missed Doses?

Patients can choose between 140 mg every 2 weeks (one prefilled syringe or autoinjector) and 420 mg once monthly (three consecutive injections using the prefilled syringe, or one session with the Pushtronex on-body infusor). Both produce equivalent LDL-C lowering at steady state [5].

Adherence data from real-world registries paint a mixed picture. The biweekly schedule requires more frequent injections, which some patients find burdensome. The monthly schedule concentrates the burden into a single session but requires administering 420 mg, which involves either three separate 140 mg injections in sequence or using the on-body infusor over approximately 5 minutes. A retrospective claims analysis of 8,618 patients on PCSK9 inhibitors found that 12-month persistence was approximately 55% for evolocumab regardless of schedule, with the most common reason for discontinuation being cost, not injection burden [6].

For patients who have difficulty remembering biweekly injections, switching to monthly dosing may consolidate the task. For patients who dislike administering three injections at once, biweekly single-injection dosing may be preferable. The missed-dose protocol is identical for both schedules. The best schedule is the one the patient will actually follow.

Practical Steps After Missing a Dose

A step-by-step protocol for patients who realize they missed their scheduled Repatha injection:

Step 1. Check the calendar. Count the days since the injection was due, not since the last injection.

Step 2. If the missed dose was due fewer than 7 days ago, prepare and administer the injection immediately using the standard technique (subcutaneous injection in the thigh, abdomen, or upper arm). Then mark the calendar with the next dose on the original schedule. Do not shift the entire schedule forward.

Step 3. If 7 or more days have passed, do not inject. Wait for the next regularly scheduled dose date and administer on time.

Step 4. If you are unsure whether the dose was actually missed (the syringe may have been partially expelled, or you cannot remember if you injected), contact your prescriber rather than re-dosing. Evolocumab is well-tolerated and a single extra dose is unlikely to cause harm, but unnecessary injections waste expensive medication. The wholesale acquisition cost for Repatha is approximately $5,850 per year, according to Amgen's 2023 list price, though net prices after rebates are substantially lower [1].

Step 5. Set a recurring reminder. Digital health platforms, smartphone alarms, and manufacturer-sponsored patient support programs (Repatha Connect) all offer reminder services. Patients who use structured reminders in clinical practice settings demonstrate higher persistence rates at 12 months [6].

What Happens to LDL-C When You Miss a Dose?

LDL-C does not snap back to pre-treatment levels after a single missed dose. Evolocumab's long half-life (11 to 17 days) provides a pharmacokinetic buffer. After a missed biweekly dose, LDL-C typically begins rising within 2 weeks and reaches a partial rebound of approximately 30 to 50 mg/dL above nadir within 3 to 4 weeks. Full return to untreated baseline requires missing several consecutive doses [2].

A pooled analysis of open-label extension studies (OSLER-1 and OSLER-2) followed 4,465 patients on evolocumab for up to 5 years [7]. LDL-C lowering remained consistent at approximately 58 to 60% throughout follow-up in adherent patients. The small subset of patients who temporarily interrupted therapy showed reversible LDL-C increases that normalized within one to two dosing cycles after re-initiation. No rebound hypercholesterolemia (LDL-C exceeding pre-treatment baseline) was observed.

This contrasts with statins, where abrupt discontinuation can trigger a transient inflammatory rebound and a brief period of LDL-C overshoot above the pre-treatment level. PCSK9 inhibitors do not share this property. Stopping and restarting evolocumab appears immunologically and metabolically safe [7].

Switching Between Dosing Schedules

Some patients find it useful to switch from biweekly to monthly dosing (or vice versa) to reduce the chance of future missed doses. The FDA label permits this switch at any time [1]. The practical approach is straightforward.

To switch from every 2 weeks to monthly: administer the first 420 mg monthly dose on the date the next 140 mg biweekly dose would have been due. To switch from monthly to every 2 weeks: administer the first 140 mg biweekly dose on the date the next 420 mg monthly dose would have been due. No washout or loading period is required. LDL-C lowering remains consistent through the transition, as the total monthly drug exposure is pharmacokinetically similar (280 mg per month for biweekly dosing vs. 420 mg per month, with minor trough differences that do not affect clinical efficacy) [5].

A prescriber should be informed before switching, because the syringe count and prior authorization requirements may differ between the two regimens depending on the patient's insurance plan.

Storage and Handling After a Delayed Dose

Repatha prefilled syringes and autoinjectors must be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) [1]. A single carton may be stored at room temperature (up to 25°C / 77°F) for a maximum of 30 days in the original packaging. Once removed from the refrigerator, do not return the product to cold storage.

If a patient misses a dose because the medication was left out beyond 30 days or was exposed to temperatures outside the labeled range, that syringe should be discarded. Do not inject medication that may have been compromised by improper storage. Contact the pharmacy for a replacement. Many specialty pharmacies will ship a replacement within 24 to 48 hours for patients enrolled in manufacturer support programs.

Special Populations and Missed-Dose Considerations

Heterozygous familial hypercholesterolemia (HeFH). The missed-dose protocol is identical to the general population. However, patients with HeFH often have higher baseline LDL-C (typically 190 to 400 mg/dL untreated), so the absolute LDL-C rebound from a missed dose is larger. A patient whose LDL-C dropped from 250 to 75 mg/dL on combination statin-plus-evolocumab therapy might see a transient rise to 110 to 130 mg/dL after one missed dose. While this is still well below untreated levels, the 2018 AHA/ACC cholesterol guideline emphasizes sustained LDL-C lowering for maximum atherosclerotic plaque regression [8].

Homozygous familial hypercholesterolemia (HoFH). Evolocumab is FDA-approved for HoFH at 420 mg monthly. Response is diminished in patients with null-null LDLR mutations (both alleles nonfunctional), because the drug's mechanism depends on upregulating residual LDL receptor activity [1]. Missed doses in this population may have less impact on LDL-C simply because the baseline response is smaller, but adherence remains important for the subset of HoFH patients who do respond.

Renal and hepatic impairment. No dose adjustment is required for mild to moderate renal or hepatic impairment. Monoclonal antibodies are cleared by proteolytic degradation, not renal or hepatic metabolism [1]. The missed-dose protocol does not change for these patients.

Pediatric patients. Evolocumab is approved for HeFH in patients aged 10 years and older at 140 mg every 2 weeks or 420 mg monthly, subcutaneous. The same 7-day missed-dose rule applies. Caregivers should be trained on the protocol during the initial prescribing visit.

Drug Interactions and Missed-Dose Timing

Evolocumab has no known clinically significant drug-drug interactions [1]. Statins, ezetimibe, fibrates, bile acid sequestrants, and PCSK9 inhibitors can be used concomitantly without dose adjustment. A missed evolocumab dose does not require changes to any concomitant lipid-lowering therapy. Patients should continue their statin and other oral medications as prescribed, regardless of whether the evolocumab injection is on schedule.

One practical consideration: patients who take evolocumab and a statin may experience more noticeable muscle symptoms during a period of missed PCSK9 inhibitor doses, because the transient LDL-C rise may prompt a prescriber to consider intensifying the statin. This is generally unnecessary if the patient resumes evolocumab on schedule. A single missed dose does not warrant a change in background statin intensity.